Navigation Links
Rigel to Present at Bank of America Merrill Lynch Health Care Conference
Date:5/5/2011

SOUTH SAN FRANCISCO, Calif., May 5, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Ryan Maynard, the company's chief financial officer, is scheduled to present a company overview at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Tuesday, May 10th at 10:00 a.m. PT.

(Logo: http://photos.prnewswire.com/prnh/20030226/RIGLLOGO)

The presentation will be webcast live and can be accessed at www.rigel.com.  Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral syk inhibitor that has started its phase 3 clinical trial program for rheumatoid arthritis, and R343, an inhaled syk inhibitor that has completed Phase 1 clinical trials for asthma.

Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Rigel Announces First Quarter Financial Results
2. Rigel Announces Fourth Quarter and Year End 2010 Financial Results
3. Rigel to Present at Three Upcoming Investor Conferences
4. Rigel Announces Participation at Two Investor Conferences
5. Rigel to Present at JP Morgan Healthcare Conference
6. Rigel Announces Third Quarter 2009 Financial Results
7. Rigel Announces Presentations at Two Investor Conferences
8. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
9. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
10. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
11. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... IRVING, Texas , Sept. 7, 2017 /PRNewswire/ ... molecular science focused on fulfilling the promise of ... that further validate the benefits of its molecular ... Each study utilized comprehensive genomic profiling plus (CGP+) ... each individual patient,s tumor on a molecular level, ...
(Date:9/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... will be participating in the Morgan Stanley 15 th ... hotel in New York.  Zimmer Biomet will present on ... A live webcast of the presentation can ... http://investor.zimmerbiomet.com .   ...
(Date:9/6/2017)... 2017  Robert G. Szewc, M.D., is recognized by ... recognition of his contributions to the Medical field.      ... at the practice of Kidney and Hypertension Specialists, which ... hypertension solutions. He has worked in this position since ... as well as expertise in kidneys, hypertension, chronic disease ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... , ... “The Trials I Face to Receive God’s Grace”: a mesmerizing ... and goals to better one’s life through God. “The Trials I Face to Receive ... the wrong places, found a love for writing. Green feels that expressing his feelings ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... asked at a gathering of executive marketers this week about the value of ... , "Everything that has happened in business has brought us to the ...
(Date:9/20/2017)... ... ... “They Sang At Her Funeral”: a tale of murder that will bring a church ... “They Sang At Her Funeral” is the creation of published author, Annalise Harold, an ... and twelve grandchildren. Before becoming a writer, Annalise had the opportunity to relocate often ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, a leading ... Denise Flannery, to its strategic advisory and client development team. , In ... with clients across different industries to develop and implement market-justified strategies, modernize and ...
(Date:9/19/2017)... , ... September 19, 2017 ... ... that Scott McFarland has joined its executive team as the President of ... innovative value-based care management systems and contact centers. , “Scott is a ...
Breaking Medicine News(10 mins):